Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-05-16

FDA Approved: ALYACEN 7/7/7 — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)

View source ↗

Summary

FDA approved Glenmark's supplemental application for ALYACEN 7/7/7, a generic norethindrone/ethinyl estradiol oral contraceptive.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ALYACEN 7/7/7 (NORETHINDRONE AND ETHINYL ESTRADIOL)

Snippet

SUPPL AP for ALYACEN 7/7/7 (NORETHINDRONE AND ETHINYL ESTRADIOL)